Leading BioSciences Announces Appointments of James R. Neal and James Sapirstein to Board of Directors
XOMA Corporation (XOMA)
Last xoma corporation earnings: 3/10 07:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
investors.xoma.com/investor-relations
Company Research
Source: GlobeNewswire
Experienced Industry Executives Provide Company with Broad Life Science Industry Expertise Including Drug Development and Commercialization CARLSBAD, Calif., Oct. 30, 2018 (GLOBE NEWSWIRE) -- Leading BioSciences, a drug development company focused on improving human health through therapeutic protection of the Gastrobiome™, today announced the appointments of James R. Neal and James Sapirstein to its board of directors. With more than three decades of life science industry experience each, Mr. Neal and Mr. Sapirstein provide Leading BioSciences with broad expertise in such areas as drug development and commercialization, strategic business operations, financial management and business development transactions. Mr. Neal, who currently serves as chief executive officer and board member for XOMA Corporation (NASD: XOMA), has nearly 35 years of life science industry leadership experience. His expertise spans such areas as development and commercialization of novel technologies
Show less
Read more
Impact Snapshot
Event Time:
XOMA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
XOMA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
XOMA alerts
High impacting XOMA Corporation news events
Weekly update
A roundup of the hottest topics
XOMA
News
- XOMA Co. (NASDAQ: XOMA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $74.00 price target on the stock.MarketBeat
- XOMA Earns $9 Million Milestone as FDA Grants Accelerated Approval to Day One's OJEMDATM (tovorafenib) for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG) [Yahoo! Finance]Yahoo! Finance
- XOMA Earns $9 Million Milestone as FDA Grants Accelerated Approval to Day One’s OJEMDATM (tovorafenib) for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG)GlobeNewswire
- XOMA Corporation Announces Closing of Tender Offer [Yahoo! Finance]Yahoo! Finance
- XOMA Corporation Announces Closing of Tender OfferGlobeNewswire
XOMA
Earnings
- 11/7/23 - Miss
XOMA
Sec Filings
- 4/25/24 - Form 8-K
- 4/3/24 - Form 8-K
- 4/2/24 - Form ARS
- XOMA's page on the SEC website